Avalide Related Published Studies
Well-designed clinical trials related to Avalide (Irbesartan / Hydrochlorothiazide)
A comparison of the efficacy and safety of irbesartan/hydrochlorothiazide combination therapy with irbesartan monotherapy in the treatment of moderate or severe hypertension in diabetic and obese hypertensive patients: a post-hoc analysis review. [2011.07]
Comparative bioavailability of two irbesartan/hydrochlorothiazide tablet formulations in Indonesian healthy subjects. [2010]
Comparison of the antihypertensive efficacy of irbesartan/HCTZ and valsartan/HCTZ combination therapy: impact of age and gender. [2010]
Safety and tolerability of fixed-dose irbesartan/hydrochlorothiazide for rapid control of severe hypertension. [2009.10]
Raltegravir. [2008]
Efficacy and safety of irbesartan/HCTZ combination therapy as initial treatment for rapid control of severe hypertension. [2006.12]
Irbesartan/HCTZ fixed combinations in patients of different racial/ethnic groups with uncontrolled systolic blood pressure on monotherapy. [2006.04]
Ambulatory blood pressure comparison of the anti-hypertensive efficacy of fixed combinations of irbesartan/hydrochlorothiazide and losartan/hydrochlorothiazide in patients with mild-to-moderate hypertension. [2005.11]
Effect of delapril-manidipine combination vs irbesartan-hydrochlorothiazide combination on fibrinolytic function in hypertensive patients with type II diabetes mellitus. [2004.10]
[Comparison of the antihypertensive activity of fosinopril and irbesartan] [2002.11]
Regression of left ventricular hypertrophy in human hypertension with irbesartan. [2001.06]
Long-term safety and antihypertensive efficacy of irbesartan: pooled results of five open-label studies. [1999.11]
The antihypertensive efficacy of the combination of irbesartan and hydrochlorothiazide assessed by 24-hour ambulatory blood pressure monitoring. Irbesartan Multicenter Study Group. [1999.11]
The long-term antihypertensive activity and tolerability of irbesartan with hydrochlorothiazide. [1999.10]
Matrix study of irbesartan with hydrochlorothiazide in mild-to-moderate hypertension. [1999.08]
Irbesartan reduces QT dispersion in hypertensive individuals. [1999.02]
The effects of irbesartan added to hydrochlorothiazide for the treatment of hypertension in patients non-responsive to hydrochlorothiazide alone. [1998.12]
Comparison of irbesartan vs felodipine in the regression after 1 year of left ventricular hypertrophy in hypertensive patients (the SILVER trial). Study of Irbesartan in Left VEntricular hypertrophy Regression. [1998.07]
An elective-titration study of the comparative effectiveness of two angiotensin II-receptor blockers, irbesartan and losartan. Irbesartan/Losartan Study Investigators. [1998.05]
Dose-related antihypertensive effects of irbesartan in patients with mild-to-moderate hypertension. [1998.04]
Comparison of the angiotensin II receptor antagonist irbesartan with atenolol for treatment of hypertension. [1998.01]
Well-designed clinical trials possibly related to Avalide (Irbesartan / Hydrochlorothiazide)
Efficacy and safety of two treatment combinations of hypertension in very elderly patients. [2009.05]
A home blood pressure monitoring study comparing the antihypertensive efficacy of two angiotensin II receptor antagonist fixed combinations. [2005.11]
Enhanced platelet release of superoxide anion in systemic hypertension: role of AT1 receptors. [2004.06]
A review of olmesartan medoxomil monotherapy: antihypertensive efficacy similar to that of other angiotensin II receptor blocker/hydrochlorothiazide combinations? [2002.11]
Effect of crossing over hypertensive patients from a beta-blocker to an angiotensin receptor antagonist on resistance artery structure and on endothelial function. [2002.01]
Other research related to Avalide (Irbesartan / Hydrochlorothiazide)
Effects of nebivolol or irbesartan in combination with hydrochlorothiazide on vascular functions in newly-diagnosed hypertensive patients: The NINFE (Nebivololo, Irbesartan Nella Funzione Endoteliale) study. [2011.11.09]
Efficacy and safety of irbesartan/HCTZ in severe hypertension according to cardiometabolic factors. [2010.07.01]
Efficacy and safety of irbesartan/HCTZ in severe hypertension according to
cardiometabolic factors. [2010]
The risks and benefits of initial irbesartan/hydrochlorothiazide combination therapy in patients with severe hypertension. [2009.05]
Irbesartan/Hydrochlorothiazide for the treatment of isolated systolic hypertension: a subgroup analysis of the INCLUSIVE trial. [2009.04]
Fixed combination of irbesartan and hydrochlorothiazide in the management of hypertension. [2009]
Cost-effectiveness of irbesartan/hydrochlorothiazide in patients with hypertension: an economic evaluation for Sweden. [2008.12]
Antihypertensive efficacy and tolerability of irbesartan/hydrochlorothiazide in hypertensive patients stratified by body mass index and type 2 diabetes mellitus status: a post hoc subgroup analysis of the Irbesartan/HCTZ Blood Pressure Reductions in Diverse Patient Populations trial. [2008.12]
Effect of irbesartan on erectile function in patients with hypertension and metabolic syndrome. [2008.09]
Efficacy and safety of fixed combinations of irbesartan/hydrochlorothiazide in hypertensive women: the inclusive trial. [2008.07]
Predictors of blood pressure response to angiotensin receptor blocker/diuretic combination therapy: a secondary analysis of the irbesartan/hydrochlorothiazide blood pressure reductions in diverse patient populations (INCLUSIVE) study. [2008.01]
Efficacy and safety of fixed combinations of irbesartan/hydrochlorothiazide in older vs younger patients with hypertension uncontrolled with monotherapy. [2008.01]
The efficacy and safety of initial use of irbesartan/hydrochlorothiazide fixed-dose combination in hypertensive patients with and without high cardiovascular risk. [2007.12]
Initial combination therapy with irbesartan/hydrochlorothiazide for hypertension: an analysis of the relationship between baseline blood pressure and the need for combination therapy. [2007.12]
Maximising antihypertensive effects of angiotensin II receptor blockers with thiazide diuretic combination therapy: focus on irbesartan/hydrochlorothiazide. [2007.12]
BP goal achievement in patients with uncontrolled hypertension : results of the treat-to-target post-marketing survey with irbesartan. [2007]
Antihypertensive efficacy of Irbesartan/HCTZ in men and women with the metabolic syndrome and type 2 diabetes. [2006.07]
Pharmacokinetic and pharmacodynamic interaction between irbesartan and hydrochlorothiazide in renal hypertensive dogs. [2005.12]
[Observational study of blood pressure control and microalbuminuria in type 2 diabetics on irbesartan or irbesartan/HCTZ] [2005.10.06]
The efficacy and safety of low- and high-dose fixed combinations of irbesartan/hydrochlorothiazide in patients with uncontrolled systolic blood pressure on monotherapy: the INCLUSIVE trial. [2005.10]
Effect of three months' treatment with irbesartan on blood and pulse pressure of hypertensive type 2 diabetic patients: open, observational study in 31,793 patients. [2005.09]
The effect of irbesartan in reducing cardiovascular risk in hypertensive type 2 diabetic patients: an observational study in 16,600 patients in primary care. [2004.10]
Irbesartan: a review of its use in hypertension and in the management of diabetic nephropathy. [2004]
Once-daily fixed-combination irbesartan 300 mg/ hydrochlorothiazide 25 mg and circadian blood pressure profile in patients with essential hypertension. [2003.11]
[IRMA-pRAcs: irbesartan in the treatment of microalbuminuria and proteinuria in patients with type 2 diabetes and hypertension-prospective observational study involving 38,016 patients in the general practice setting] [2003.10.09]
AT1-receptor antagonism in hypertension: what has been learned with irbesartan? [2003.05]
[Effect of anti-hypertensive therapy with irbesartan on the absolute cardiovascular risk] [2003.04]
Irbesartan lowers superoxide levels and increases nitric oxide bioavailability in blood vessels from spontaneously hypertensive stroke-prone rats. [2002.02]
The pharmacokinetics of irbesartan in hypertensive children and adolescents. [2001.07]
Drug interactions with irbesartan. [2001]
Differential effects of enalapril and irbesartan in experimental papillary necrosis. [2001]
Irbesartan: an updated review of its use in cardiovascular disorders. [2000.05]
Clinical overview of irbesartan: expanding the therapeutic window in hypertension. [1997.12]
Irbesartan. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in the management of hypertension. [1997.12]
Other possibly related research studies
A meta-analytical approach to the efficacy of antihypertensive drugs in reducing blood pressure. [2005]
Antihypertensive efficacy of angiotensin receptor blockers in combination with hydrochlorothiazide: a review of the factorial-design studies. [2004.10]
Olmesartan compared with other angiotensin II receptor antagonists: head-to-head trials. [2004]
Reasons for not intensifying antihypertensive treatment (RIAT): a primary care antihypertensive intervention study. [2004.06]
Acute pancreatitis associated with angiotensin II receptor antagonists. [2002.12]
Pharmacological prevention and regression of arterial remodeling in a rat model of isolated systolic hypertension. [2002.08]
Gateways to clinical trials. [2002.05]
Achieving blood pressure targets in the management of hypertension. [2001]
Clinical differences among angiotensin II receptor antagonists. [2001]
Lercanidipine: a review of its use in hypertension. [2000.11]
Clinical pharmacokinetics of angiotensin II (AT1) receptor blockers in hypertension. [2000.04]
Angiotensin II antagonists for hypertension: are there differences in efficacy? [2000.04]
Efficacy of angiotensin II antagonists in hypertension. [1999.11]
Efficacy and safety of two treatment combinations of hypertension in very elderly patients. [2008.05.03]
|
